Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials

INTRODUCTION: We analyzed phase 3 trial data of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) ± ribavirin (RBV) in genotype 1 chronic hepatitis C patients to investigate the impact of 3D ± RBV on renal, cardiovascular and metabolic extrahepatic manifestations (EHMs), including persistency 52 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Darshan A., Cohen, Eric, Charafeddine, Mariem, Cohen, Daniel E., Bao, Yanjun, Sanchez Gonzalez, Yuri, Tran, Tram T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700891/
https://www.ncbi.nlm.nih.gov/pubmed/28939957
http://dx.doi.org/10.1007/s40121-017-0171-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700891/
https://www.ncbi.nlm.nih.gov/pubmed/28939957
http://dx.doi.org/10.1007/s40121-017-0171-0

Ejemplares similares